The Infusion Reimbursement Index, Issue 01 (2026-Q2): commercial contracted rates for infused drugs vs. the Medicare payment limit

What commercial health insurers contract to pay for infused and injected (J-code) drugs, benchmarked to Medicare's Part B payment limit. Built by CareCost from the Transparency-in-Coverage machine-readable files that insurers are required to publish (37 insurer filings, vintage 2026-Q2). Scale: every index column ends in _pl100. 100 = the CMS Medicare Part B payment limit (ASP + 6%) for the same drug and quarter. About 94.3 = ASP; about 96.9 = typical non-340B acquisition cost (ASP + 2.7%). These are contracted rates from insurers' published files, not amounts paid on claims. Correction note. Report Issue 01 first labeled this scale "ASP = 100"; the label was corrected on 22 September 2026. This deposit uses the corrected label and removes columns that compared against the mislabeled reference lines (see README and METHODOLOGY-issue01.md). Ratios, grades, and spreads are unaffected. Files: drug-reference.csv (806 drugs), payer-scorecard.csv (57 insurers), fee-schedule-census.csv (37 filings), README.md, METHODOLOGY-issue01.md. Full report and interactive lookup: carecostestimate.com/infusion-index.